文献速递传染病防控与疫情报告免疫规划

曾接种1剂JYNNEOS疫苗者与未接种者中猴痘的人口学与临床特征——美国29个辖区,2022年5月22日至9月3日

Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons - 29 U.S. Jurisdictions, May 22-September 3, 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-12-30

分析美国29个辖区14504例猴痘病例中6605例有疫苗接种信息者,其中276例(4.2%)在发病前≥14天接种过1剂JYNNEOS疫苗。与未接种者相比,接种者住院比例较低(2.1% vs 7.5%),发热、头痛、不适、肌痛和寒战也较少。1剂疫苗可提供一定保护,但接种后仍可能感染,保护持续时间未知,应鼓励高危人群完成2剂接种。

要点

  • 在纳入分析的6605例猴痘病例中,276例(4.2%)在发病前≥14天接种过1剂JYNNEOS疫苗。
  • 接种1剂者住院比例为2.1%,未接种者为7.5%,发热、头痛、不适、肌痛和寒战也较少。
  • 1剂疫苗可提供一定保护,但接种后仍可能感染,保护持续时间未知,应鼓励完成2剂接种。

核心结论

  • 1剂JYNNEOS疫苗可提供一定保护,但接种后仍可能发生猴痘感染,且1剂疫苗的保护持续时间未知。
  • 提供者与公共卫生官员应鼓励有猴痘感染风险者完成2剂疫苗接种系列,并提供非疫苗相关预防策略的指导与教育。

研究设计与样本

  • 分析2022年5月22日至9月3日美国29个参与辖区报告的14504例猴痘病例,其中6605例(45.5%)有可用疫苗接种信息并纳入分析。
  • 比较发病前≥14天接种1剂JYNNEOS疫苗者与未接种者的猴痘病例人口学与临床特征,并与参与辖区疫苗符合接种条件人群比较。

主要发现

  • 纳入分析的6605例中,276例(4.2%)为发病前≥14天接种1剂JYNNEOS疫苗者。
  • 接种1剂者猴痘病例的住院比例为2.1%,未接种者为7.5%。
  • 与未接种者相比,接种1剂者的猴痘病例中发热、头痛、不适、肌痛和寒战的比例较低。

关键数值与推荐

  • JYNNEOS疫苗于2019年获美国食品药品监督管理局(FDA)批准为2剂系列(每剂0.5 mL,皮下注射),用于预防天花和猴痘疾病。
  • 2022年8月9日,FDA发布紧急使用授权,允许JYNNEOS疫苗皮内注射(每剂0.1 mL)。

临床怎么用

  • 提供者与公共卫生官员应鼓励有猴痘感染风险者完成2剂JYNNEOS疫苗接种系列。
  • 提供者与公共卫生官员应提供非疫苗相关预防策略的指导与教育。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As of November 14, 2022, monkeypox (mpox) cases had been reported from more than 110 countries, including 29,133 cases in the United States.* Among U.S. cases to date, 95% have occurred among males (1). After the first confirmed U.S. mpox case on May 17, 2022, limited supplies of JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic) were made available to jurisdictions for persons exposed to mpox. JYNNEOS vaccine was approved by the Food and Drug Administration (FDA) in 2019 as a 2-dose series (0.5 mL per dose, administered subcutaneously) to prevent smallpox and mpox disease.† On August 9, 2022, FDA issued an emergency use authorization to allow administration of JYNNEOS vaccine by intradermal injection (0.1 mL per dose) (2). A previous report on U.S. mpox cases during July 31-September 3, 2022, suggested that 1 dose of vaccine offers some protection against mpox (3). This report describes demographic and clinical characteristics of cases occurring ≥14 days after receipt of 1 dose of JYNNEOS vaccine and compares them with characteristics of cases among unvaccinated persons with mpox and with the vaccine-eligible vaccinated population in participating jurisdictions. During May 22-September 3, 2022, among 14,504 mpox cases reported from 29 participating U.S. jurisdictions,§ 6,605 (45.5%) had available vaccination information and were included in the analysis. Among included cases, 276 (4.2%) were among persons who had received 1 dose of vaccine ≥14 days before illness onset. Mpox cases that occurred in these vaccinated persons were associated with lower percentage of hospitalization (2.1% versus 7.5%), fever, headache, malaise, myalgia, and chills, compared with cases in unvaccinated persons. Although 1 dose of JYNNEOS vaccine offers some protection from disease, mpox infection can occur after receipt of 1 dose, and the duration of protection conferred by 1 dose is unknown. Providers and public health officials should therefore encourage persons at risk for acquiring mpox to complete the 2-dose vaccination series and provide guidance and education regarding nonvaccine-related prevention strategies (4).

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Farrar JL, Lewis NM, Houck K, et al. Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons - 29 U.S. Jurisdictions, May 22-September 3, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36580416. doi:10.15585/mmwr.mm715152a2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。